Aimei Health Receives Nasdaq Notices Over Market-Value Shortfalls

What Happened
Aimei Health Technology Co., Ltd. (ticker: AFJK) filed an 8‑K on August 25, 2026 reporting that on August 21, 2026 Nasdaq’s Listing Qualifications Department notified the company that its Market Value of Listed Securities (MVLS) and Market Value of Publicly Held Shares (MVPHS) were below Nasdaq Global Market minimums for the prior 30 consecutive business days. The notices do not remove the company’s shares from listing immediately; trading under AFJK continues while the company has a 180‑day compliance period to regain the required market values.

Key Details

• Nasdaq found MVLS below the $50,000,000 requirement (Nasdaq Listing Rule 5450(b)(2)(A)) and MVPHS below the $15,000,000 requirement (Rule 5450(b)(2)(C)).
• Notices were received August 21, 2026; the compliance deadline for each deficiency is 180 days (until February 17, 2027).
• To regain compliance, MVLS or MVPHS must close at or above the respective threshold for 10 consecutive business days; Nasdaq will then confirm compliance in writing.
• If the company does not regain compliance, Nasdaq will notify it that its securities are subject to delisting; the company may consider applying to transfer to The Nasdaq Capital Market if eligible.

Why It Matters
This filing signals a heightened listing risk: if Aimei Health cannot restore its market values by Feb 17, 2027, its shares could be delisted or moved to a different Nasdaq tier, which can affect liquidity, investor access, and perceptions of the company. The company says it will monitor MVLS and MVPHS and consider options to regain compliance, but there is no assurance it will succeed. Investors should watch market‑value trends and company updates on efforts to remedy the deficiency.